Is Mounjaro FDA-approved for PCOS?

No. Mounjaro is FDA-approved to improve blood sugar in people age 10 and up with type 2 diabetes. PCOS is not an approved use for Mounjaro or any GLP-1 medication, though a 72-week clinical trial is currently testing tirzepatide in women with PCOS.

Can my doctor prescribe Mounjaro for PCOS anyway?

Yes -- doctors can legally prescribe medicines off-label when they believe it's appropriate. But a prescription and a paid claim are two different things. Insurance covers the FDA-approved use, so an off-label PCOS prescription usually means paying cash.

Does insurance cover Mounjaro for PCOS if I have prediabetes or insulin resistance?

Usually not. Plans like Cigna state in writing that diabetes prevention is not a covered use for these drugs. Prediabetes and insulin-resistance labs are still valuable -- they can support Zepbound criteria at BMI 27-29.9, count toward the Medicare GLP-1 Bridge at BMI 27+, and strengthen an appeal -- they just don't unlock Mounjaro by themselves.

What diagnosis qualifies for Mounjaro coverage?

Type 2 diabetes. Lilly's prior-authorization guide points doctors to diabetes ICD-10 codes such as E11.65, E11.8, and E11.9, plus a recent A1c and medication history. Some plans also want metformin-related documentation; others focus on documented diabetes labs and records.

Does the Mounjaro savings card work if my insurance denies coverage?

Not for an off-label use. Lilly's terms require commercial insurance and a prescription for one of Mounjaro's FDA-approved uses -- type 2 diabetes. There's a $25 tier when your plan covers Mounjaro and a $499 tier when it doesn't, but the approved-use rule applies to both, and government insurance is excluded entirely.

Is Zepbound easier to get covered than Mounjaro for PCOS?

For most people without diabetes, yes -- it contains the same active ingredient (tirzepatide) with a weight-management approval: BMI 30+, or 27+ with a weight-related condition. The catch is your plan must include a weight-loss drug benefit, which 43% of plans did in Ro's 2024-2025 coverage-check report.

Does the new Medicare program cover Mounjaro?

No. The Medicare GLP-1 Bridge, starting July 1, 2026, covers Zepbound KwikPen, Wegovy, and Foundayo for weight reduction at a flat $50/month for eligible Part D enrollees. Mounjaro remains a regular Part D medication for covered uses like type 2 diabetes.

Does Medicaid cover Mounjaro for PCOS?

Generally no. State programs typically cover Mounjaro for type 2 diabetes with prior authorization, while excluding weight-loss use -- Medi-Cal Rx in California says this outright, and Massachusetts bars paying for obesity drugs by regulation. Rules vary by state, so check your state's formulary.

Does Mounjaro affect birth control?

It can. The label warns that birth-control pills may be less effective after starting tirzepatide or increasing the dose, and advises a non-pill or backup method for four weeks after starting and after each dose increase. With PCOS, weight loss can also improve ovulation -- so an unplanned-pregnancy risk can rise exactly when you'd least expect it.

Is compounded tirzepatide an option instead?

We don't recommend it as the path here. The FDA determined the tirzepatide shortage was resolved in December 2024, with wind-down deadlines for both 503A and 503B compounders. Compounded drugs are not FDA-approved, and once a shortage ends, making copies of available FDA-approved drugs faces legal restrictions. This guide sticks to FDA-approved routes with published prices.

What about Ozempic or Wegovy for PCOS?

Different medicine (semaglutide), different coverage logic. If your plan covers Wegovy but not Zepbound -- common on some Caremark plans -- start with our Mounjaro vs Wegovy for PCOS guide, then check coverage the same way.

Does Insurance Cover Mounjaro for PCOS? (2026 Guide)

Usually no — not for PCOS alone. But there are 5 real paths to tirzepatide in 2026. Here's which one is yours.

By The RX Index Editorial TeamLast verified: June 9, 2026Next review: July 2026Affiliate disclosure

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. Some links on this page pay us a commission. That never changes a price you pay, and it never changes a fact we report. This guide is information, not medical advice — your clinician and your insurer make the final calls.

The direct answer: usually no, not for PCOS alone

Mounjaro is FDA-approved only for type 2 diabetes. So almost every insurance plan wants a diabetes diagnosis — not a PCOS diagnosis — before it pays. We won't bury that.

Here's what the other articles bury: women with PCOS still have five real paths to this medicine (tirzepatide) in 2026. Most people only know one or two of them. One path opens July 1. One depends on a single line in your plan's fine print. And one is a pricing trap that a top-ranking article gets flat wrong.

Find your answer by situation

Your situation	Will insurance pay?	Why	Your best move
PCOS plus diagnosed type 2 diabetes	Usually yes, with prior authorization	Type 2 diabetes is Mounjaro's FDA-approved use	Build the PA packet (Path 1) -- could be as little as $25 for up to a 3-month fill with Lilly's card, if eligible
PCOS only -- no diabetes	Almost always no	PCOS is an off-label use; plans pay for the approved use	Read Paths 2-5. Don't waste a month on a doomed PA
PCOS + insulin resistance or prediabetes	Still usually no -- for Mounjaro	Cigna's policy states diabetes prevention doesn't qualify	Those labs matter for Path 2, Path 4, and appeals -- not for Mounjaro itself
PCOS, no diabetes, BMI 30+	Often yes -- as Zepbound, not Mounjaro	Zepbound has the same active ingredient with a weight-management approval	Path 2: the Zepbound route
PCOS, no diabetes, BMI 27-29.9 + a condition like high blood pressure or sleep apnea	Maybe -- as Zepbound	Fits Zepbound's FDA label if your plan covers weight-loss drugs	Path 2, then check your plan's drug list
Medicare	Mounjaro: type 2 diabetes only. For weight: $50/month Bridge starts July 1, 2026 -- covers Zepbound KwikPen, not Mounjaro	CMS Medicare GLP-1 Bridge rules	Path 4
Medicaid	Type 2 diabetes: often yes. PCOS or weight: generally no	State rules; some ban paying for any weight-loss drug	Path 4
Paying cash	No insurance needed	The smart cash price is Zepbound at $299-$449/month, not Mounjaro at ~$1,100	Path 5
Trying to conceive, pregnant, or on the pill	Coverage isn't your first question -- safety is	Tirzepatide and pregnancy don't mix well, and it can affect birth-control pills	Read the safety section before anything else

The fastest way to turn that table into your answer: find out what your plan actually covers before your doctor sends anything. Ro built a free tool for exactly this — its insurance team contacts your plan and sends you a written report showing which GLP-1 medications are covered, whether prior authorization is required, and your estimated copay.

See exactly what your plan covers — run Ro's free GLP-1 Insurance Coverage Checker →

Free. No membership needed to check. Ro doesn't sell Mounjaro itself — more on that below.

What we actually verified

Last verified June 9, 2026. For this guide, we read Mounjaro's and Zepbound's current FDA labeling, Eli Lilly's official Savings Card terms and prior-authorization guide, public payer policies (Cigna, Aetna, UnitedHealthcare, Blue Cross Blue Shield of Massachusetts, Medi-Cal Rx), CMS's Medicare GLP-1 Bridge rules, LillyDirect's self-pay pricing terms, public state appeal records, and Ro's free GLP-1 Insurance Coverage Checker. Every price and policy below links to the source we read.

Why won't insurance cover Mounjaro for PCOS alone?

Insurance plans cover Mounjaro based on its FDA-approved use, which is type 2 diabetes — not PCOS. A PCOS prescription is “off-label,” meaning a doctor can legally write it, but the plan has no obligation to pay for it. The diagnosis code on the prescription is the first thing the insurer checks, and an off-label code stops the claim before medical need is ever considered.

Your insurance company doesn't start by asking, “Would this drug help her?” It starts with one colder question: “Does the diagnosis code match the approved use?” The code is the first gate. If it matches, the insurer moves on to your chart notes, labs, medication history, and your plan's own rules. If it doesn't match, nothing else gets read.

Code on the claim	What it means	What happens to a Mounjaro request
E28.2 (PCOS)	Off-label for Mounjaro	Stops at the first gate — denied
E11.x (type 2 diabetes)	Matches Mounjaro's FDA label	Moves to prior-authorization review (Path 1)
Obesity / BMI codes (E66, Z68.3x)	Wrong drug name, right idea	Points to Zepbound, the weight-management brand (Path 2)

Mounjaro's label covers one thing: improving blood sugar in people age 10 and up with type 2 diabetes. PCOS is the most common hormone condition in women of reproductive age, and insulin resistance — one of the main reasons this drug class comes up in PCOS conversations — sits at the center of it for many women. Per the CDC, more than half of women with PCOS develop type 2 diabetes by age 40. A 72-week, placebo-controlled clinical trial is underway right now testing whether tirzepatide improves ovarian function and menstrual regularity in women with PCOS. Until results change the label, insurers will keep pointing at the diabetes-only approval.

That's the wall. Now here are the five doors through it.

Path 1: What diagnosis actually gets Mounjaro covered?

A documented type 2 diabetes diagnosis is the diagnosis that gets Mounjaro covered. Most plans require the diabetes code (such as ICD-10 E11.65, E11.8, or E11.9) plus medical records confirming the diagnosis — and depending on the plan, metformin history or other step-therapy records. PCOS, insulin resistance, and prediabetes do not meet most plans' Mounjaro criteria on their own.

This matters for more PCOS readers than you'd think. According to the CDC, more than half of women with PCOS develop type 2 diabetes by age 40. Some of you reading this already qualify for Mounjaro on-label — and don't know it because nobody has run your labs lately.

Here is what major payers actually require:

Payer / plan	What their policy requires	Covers Mounjaro for PCOS alone?
Cigna (individual & family plans)	Documented type 2 diabetes; the policy states weight loss and diabetes prevention are not covered uses	No
Aetna	Type 2 diabetes diagnosis under its authorization criteria, with metformin-related documentation	No
UnitedHealthcare (commercial)	Medical records confirming type 2 diabetes -- for example, A1c of 6.5% or higher, fasting glucose of 126 mg/dL or higher, or records of ongoing diabetes treatment	No
Blue Cross Blue Shield of Massachusetts	Mounjaro stays covered for documented type 2 diabetes with prior authorization -- while weight-loss GLP-1s like Zepbound are excluded unless the employer buys that coverage back	No
Medi-Cal Rx (California Medicaid, effective Jan 1, 2026)	Diabetes GLP-1s like Mounjaro require a type 2 diabetes diagnosis code; not covered for weight loss alone	No
Medicare Part D	Type 2 diabetes only; weight-loss use is excluded from Part D by federal law	No

If you have PCOS and type 2 diabetes, you're not off-label at all

This is the clean lane. Your doctor sends a prior authorization (a form proving you meet the plan's rules). Here's what a complete packet looks like:

What goes in the PA packet	Why it matters	Who provides it
Type 2 diabetes diagnosis code (E11.65, E11.8, E11.9, etc.)	The insurer matches it against the approved use	Your doctor
Recent A1c or glucose labs	Proves the diagnosis is current and documented	Your doctor / lab
Medication history (metformin: tried it, couldn't tolerate it, or need more)	Some plans use step therapy -- try the cheaper drug first	Your doctor / pharmacy records
Chart notes connecting the diagnosis, labs, and treatment plan	Incomplete files are how easy approvals turn into denials	Your doctor
Your plan's written PA criteria	So the file answers the actual questions, not guesses	Your insurer

Get approved, and Lilly's Mounjaro Savings Card can drop your cost to as little as $25 for up to a 3-month fill on eligible commercial insurance. See our Mounjaro Savings Card guide for exactly who qualifies.

One hard rule, and we mean it: never ask a doctor to put a diabetes code on your chart that your labs don't support. That's fraud, it puts your doctor's license at risk, and insurers audit these claims. The honest version: ask your doctor, “Do my recent labs meet the criteria for type 2 diabetes?” If yes, you were never off-label. If no, your real options are below — and they're better than most articles admit.

Grab the PA packet checklist — free PCOS GLP-1 Coverage Kit →

Gather the code, labs, medication history, and chart notes before the request goes out. Printable. No email required.

Path 2: The Zepbound route — same active ingredient, a label you might actually fit

Zepbound contains tirzepatide, the same active ingredient as Mounjaro, but it is a different brand with a different FDA-approved use: chronic weight management for adults with a BMI of 30+, or 27+ with at least one weight-related condition. For most women with PCOS who don't have type 2 diabetes, Zepbound is the realistic insurance path to tirzepatide, not Mounjaro.

You don't have to force a diabetes drug through a diabetes-only rulebook. Lilly sells tirzepatide under a second brand name with an FDA approval many PCOS readers actually fit:

BMI 30 or higher, or
BMI 27–29.9 plus at least one weight-related condition — plans typically count high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea (more common with PCOS), and on some plans, prediabetes.

Catch #1: PCOS itself usually isn't on the comorbidity list

Most plans' written criteria name conditions like hypertension and sleep apnea — not PCOS. If your BMI is 30+, this doesn't matter; you qualify on BMI alone. If you're in the 27–29.9 band, your other diagnoses (and labs you may already have from PCOS workups) do the qualifying. This is where that prediabetes or blood-pressure reading finally earns its keep.

Catch #2: your plan has to include a weight-loss drug benefit at all

This is the single line of fine print that matters most. Some employers buy it. Some don't — and some are dropping it. In Ro's published report of coverage checks run from August 2024 through April 2025, 43% of plans checked covered a GLP-1 for weight loss — while nearly all covered one for type 2 diabetes — and half of covered patients had a reported copay of $50/month or less. The only way to know which group you're in is to check — not to guess, and not to find out via a denial letter six weeks from now.

One wrinkle: some plans run by CVS Caremark moved Zepbound off their standard drug list in favor of Wegovy. If your coverage report comes back “Wegovy yes, Zepbound no,” don't fight it — read our Mounjaro vs Wegovy for PCOS guide and take the covered lane.

What Ro can and can't do — stated plainly

Ro does not sell Mounjaro, and Ro cannot get Mounjaro covered for PCOS — nobody can, because no concierge on earth can change an FDA label. If brand-name Mounjaro is your non-negotiable goal, Ro is the wrong door: work directly with your own doctor on Path 1, or book a visit through Sesame Care where you pick the prescriber and see the visit price before you book. But because Ro skips the lanes insurers always reject, it can pour everything into the lanes your plan can actually say yes to: its free Coverage Checker tells you in writing whether Zepbound (or Wegovy) is covered, and if prior authorization is required, Ro's insurance concierge handles the paperwork for you — and if your insurer denies one medication, Ro's providers check whether another covered option fits you clinically. Membership runs $39 for your first month, then as low as $74/month with an annual plan ($149/month month-to-month), on top of medication costs.

See if you qualify for Zepbound and what your plan will pay →

If your plan says yes, Ro's concierge files the prior authorization for you. If it says no, you just saved weeks.

Path 3: Denied? How to appeal — and when not to

You have the legal right to appeal an insurance denial, and appeals succeed when they answer the specific denial reason with truthful documentation that matches the plan's written criteria. Public appeal records show the pattern clearly: denials for obesity or PCOS-only diagnoses get upheld, while denials get overturned when the file documents an on-label diagnosis with dated treatment history.

What losing looks like (real appeal records)

In Massachusetts, a patient requested Mounjaro for obesity after trying surgery, diet, and exercise. MassHealth denied it and the hearing officer upheld the denial — because state regulation bars paying for any drug used to treat obesity. In a second case, the patient explained she had a family history of diabetes and was paying out of pocket to avoid becoming diabetic herself. Sympathetic? Completely. Approved? No — the diagnosis on the request was obesity. Sympathy doesn't move these decisions. Documentation does.

What winning looks like (real appeal records)

In New York, Aetna denied Mounjaro for a patient — and an independent reviewer overturned the denial. Why? She had documented type 2 diabetes, plus dated records showing she'd tried and failed metformin, Trulicity, Ozempic, and Victoza, with the specific side effects that stopped each one. That's the anatomy of a winning file: on-label diagnosis + specific, dated history. Nothing emotional. Everything documented.

Your appeal, step by step:

Get the denial reason in writing. It'll say something like “diagnosis not covered,” “step therapy required,” “not medically necessary,” or “weight-loss drugs excluded.” The reason determines everything you do next.
Find your deadline and calendar it first. Your denial letter lists the appeal deadline. Put that date on your calendar before you do anything else.
Ask for the plan's written PA criteria. The exact phone script is in the insurer-questions section below — use it word for word.
Match your evidence to the denial reason, point by point. Diagnosis code, labs, dated medication history, chart notes, your doctor's letter. The strongest appeals quote the plan's own criteria back to it and check every box.
Know when not to appeal. Two situations waste your time. First: if the denial says “Mounjaro is limited to type 2 diabetes” and you don't have type 2 diabetes, an appeal is a slow way to lose. Second: if your plan excludes weight-loss drugs entirely, that's a benefit exclusion, not a coverage decision — it can't be appealed. In both cases, your faster wins are the Zepbound benefit check (Path 2) or self-pay (Path 5).

Download the free PCOS GLP-1 Coverage Kit — appeal letter template included →

The fill-in appeal letter, the doctor-visit checklist, and the insurer call script — printable, no email required.

Path 4: Does Medicare or Medicaid cover Mounjaro for PCOS?

No — Medicare Part D covers Mounjaro when prescribed for a covered use like type 2 diabetes, and Medicaid programs broadly exclude weight-loss use. Starting July 1, 2026, the Medicare GLP-1 Bridge covers Zepbound KwikPen, Wegovy, and Foundayo for weight reduction at a flat $50 per month for eligible Part D enrollees. Mounjaro itself is not included in the Bridge.

The Medicare GLP-1 Bridge, in plain English:

Starts July 1, 2026 and runs through December 31, 2027, per CMS.
Covers three medicines for weight reduction: Zepbound (KwikPen form only), Wegovy (shots and pills), and Foundayo. Mounjaro is not on the list.
You pay a flat $50 a month, no matter the dose. Cash prices for these drugs run $149 to $699 a month.
Qualifying rules per CMS: 18 or older, in a Part D plan, prescribed for weight reduction, and at the time you start therapy: BMI 35+; or BMI 30+ with heart failure (preserved ejection fraction), uncontrolled high blood pressure, or stage 3a+ chronic kidney disease; or BMI 27+ with prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

Read that last rule: prediabetes at BMI 27+ counts here. The lab result that couldn't unlock Mounjaro can help unlock the Bridge.

The Bridge fine print: the $50 sits outside your normal Part D benefit. It doesn't count toward your deductible or your $2,100 yearly out-of-pocket cap, Extra Help doesn't lower it, and you can't stack coupons on it. Your doctor submits the prior authorization through the program's central process. And if your GLP-1 qualifies under a regular Part D use — like type 2 diabetes or sleep apnea — it goes through your Part D plan instead, not the Bridge.

Medicaid is a state-by-state patchwork. Most states cover Mounjaro for type 2 diabetes with prior authorization. For PCOS or weight loss, the answer is generally no — California's Medi-Cal Rx spells it out directly, and Massachusetts bars paying for obesity drugs by regulation. One more thing: Lilly's savings cards don't work with any government insurance — Medicare, Medicaid, TRICARE, or VA. Don't let a pharmacy visit be how you find that out.

No affiliate links in this section on purpose. For Medicare questions beyond this page, the CMS Bridge page and the Medicare Rights Center are the sources we'd send our own parents to.

Path 5: What does Mounjaro cost for PCOS without insurance in 2026?

Mounjaro's list price is $1,112.16 per month, and cash prices with discount cards run about $1,051–$1,120. Lilly's savings card requires a prescription for an FDA-approved use, so an off-label PCOS prescription generally does not qualify for the $25 or $499 card tiers. The affordable legitimate path to the same active ingredient is Zepbound, sold directly by Lilly for $299–$449 per month.

The trap we promised to call out

A currently top-ranking article claims you can get Mounjaro for $25 a month “regardless of whether your insurance denies coverage for PCOS.” That is not what Lilly's terms say. Read the official Savings Card terms yourself: both card tiers require commercial insurance and “a prescription for an approved use consistent with FDA-approved product labeling.” Mounjaro's approved use is type 2 diabetes. A PCOS-only prescription is not an approved use. Plan around the real rules, not the headline.

Every legitimate way to pay for tirzepatide in 2026, in one place:

Path	Who it's for	Monthly cost	The fine print
Mounjaro + insurance + Lilly card	Commercial plan covers it (requires a type 2 diabetes prescription)	As little as $25 for up to a 3-month fill	Card expires 12/31/2026; approved-use rule applies
Mounjaro card, plan doesn't cover it	Commercial insurance, no coverage -- and an approved-use prescription	As low as $499	Max savings $647/month, $8,411/year; the approved-use rule still applies
Mounjaro, pure cash	Anyone with a prescription	~$1,051-$1,120 with discount cards	No generic is coming for years
Zepbound through insurance + Lilly card	Plan includes a weight-loss benefit; you meet BMI criteria	As little as $25/month	Roughly 43% of plans had the benefit in Ro's checked sample
Zepbound self-pay via LillyDirect (single-dose vial or KwikPen)	No insurance needed	$299 (2.5mg) / $399 (5mg) / $449 (7.5-15mg)	The $449 tier requires refilling within 45 days -- set a phone reminder for day 30
Zepbound vial via TrumpRx (government direct-purchase site)	No insurance needed	Starting at $299 out of pocket	Born from the November 2025 White House-Lilly pricing deal; eligibility and terms apply
Medicare GLP-1 Bridge	Eligible Part D enrollees, starting July 1, 2026	$50 flat, any dose	Zepbound KwikPen only -- see Path 4

Brand Mounjaro for an off-label use costs roughly $13,000 a year. The same active ingredient, bought as Zepbound straight from the manufacturer, costs $3,600–$5,400 a year — no insurance fight required. Same active ingredient. Same manufacturer. A 60–70% price difference that exists entirely because of which brand is on the box and which diagnosis is on the script. (Prescribed medication costs are generally HSA/FSA-eligible — confirm with your plan administrator.)

If you're going the cash route and want a clinician to walk your options first — including whether your labs change the picture — that's one telehealth visit, not a project:

Book a visit on Sesame Care — pick your clinician and see the visit price before you book →

Good fit if you want a real conversation about Mounjaro vs. Zepbound without a membership. Sponsored affiliate link.

Does Mounjaro even work for PCOS? What the evidence says so far

Tirzepatide is not FDA-approved for PCOS, and the trials designed to prove PCOS-specific benefits are still running. The largest real-world dataset reported to date — 4,241 women with self-reported PCOS and overweight or obesity, presented as a conference abstract at ObesityWeek 2025 — found average weight loss of about 18.8% at 10 months, with over 90% losing at least 10% of their body weight. It measured weight, not PCOS symptoms, and was not an FDA-reviewed trial.

We're keeping this section short on purpose, because hype is the last thing this topic needs. What's actually known:

ObesityWeek 2025 data

4,241 women with self-reported PCOS using tirzepatide through a digital weight-loss program in the UK. Average weight loss of 18.8% at 10 months; over 90% lost at least 10% of their body weight. In PCOS, even a 5% weight reduction is associated with improvements in symptoms and insulin resistance. But know the limits: it was retrospective, presented as a conference abstract, and it didn't measure cycles, fertility, or hormone levels.

The 2023 international PCOS guideline

Still puts lifestyle change first and metformin as the usual add-on — which, not coincidentally, is exactly why insurers ask about metformin before approving anything stronger. GLP-1 medicines get a cautious “could be considered” for higher-weight adults with PCOS, with heavy emphasis on contraception and shared decision-making.

The ongoing 72-week PCOS trial

The clearest signal of all: the answer science can currently give is “promising for weight, unproven for PCOS itself, ask again in a couple of years.”

Whether any of this fits your health picture is a conversation for your clinician — not a comment section, and not us.

Safety notes your doctor will bring up (especially with PCOS)

Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in animal studies and must not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Human pregnancy data are insufficient — and for PCOS patients specifically, guidelines stress effective contraception, because the medicine can make birth-control pills less effective, while weight loss itself can improve ovulation.

1. The pregnancy double-bind

Mounjaro's label says human pregnancy data are insufficient and animal studies showed risk — so plan as if pregnancy and this medicine don't mix. At the same time, the international PCOS guideline notes that weight loss can improve ovulation, and it specifically tells women using GLP-1 medicines to use effective contraception when pregnancy is possible. Put plainly: a medicine you shouldn't get pregnant on can raise your odds of getting pregnant. Decide your plan before dose one.

2. The pill gets less reliable

The label warns that birth-control pills may not work as well after you start tirzepatide or raise your dose, and advises switching to a non-pill method or adding a backup method for four weeks after starting and four weeks after each dose increase.

3. The standard list

Boxed warning (thyroid C-cell tumors in rodent studies; do not use with a personal or family history of medullary thyroid cancer or MEN 2), and stomach side effects — nausea, vomiting, diarrhea — are the most common reason people struggle early on.

None of this is a reason to panic. All of it is a reason the right next step is a clinician who knows your chart — and why every button on this page says “check” and not “buy.”

What should you ask your insurer before your doctor sends the prescription?

Before any prescription goes out, ask your insurer whether Mounjaro is on the formulary, whether a type 2 diabetes diagnosis is required, whether prior authorization or step therapy applies, whether Zepbound or other weight-management GLP-1s are covered, whether weight-loss drugs are excluded from your plan entirely, and what the appeal deadline is if you're denied.

Call the number on the back of your insurance card and read this, word for word:

“I have PCOS and my clinician is considering GLP-1 treatment. Is Mounjaro covered under my pharmacy benefit, and does coverage require a type 2 diabetes diagnosis? What prior-authorization criteria apply — can you send them to me in writing? Is step therapy required? Are Zepbound or other weight-management GLP-1 medications covered, or are weight-loss drugs excluded from my plan? What would my copay be after approval? And if a request is denied, what is the appeal deadline?”

Then write down four things: the date, the rep's name or reference number, the answers, and the appeal deadline. That call log goes in your folder next to your labs — and if you ever appeal, “per my call on [date], reference [number]” is a sentence insurers take seriously.

Prefer the answers in writing without making the call yourself? That's what the free coverage check does — same questions, asked by Ro's insurance team, returned as a report you can hand your doctor.

Your 7-day plan to get a real answer

Within one week, you can know which path is yours: check what your plan actually covers, get the right labs ordered, and walk into one appointment with documentation that matches a real coverage pathway — instead of spending months on guess-and-deny.

Day 1

Run the free coverage check -- or make the insurer call using the script above. Either way, you're answering the same two questions: Is Mounjaro covered, and does it require a type 2 diabetes diagnosis? And: Are Zepbound or other weight-management GLP-1s covered on my plan?

Day 2

Download the Coverage Kit and pull what you already have: last A1c, recent weight/BMI, blood pressure readings, any sleep-apnea or cholesterol diagnoses, and your metformin history with dates.

Day 3-5

Book the appointment. Bring the checklist. Ask the two questions that decide everything: Do my labs meet the criteria for type 2 diabetes? And: If not, do I meet Zepbound's BMI criteria?

Day 5-6

If a prior authorization is needed, make sure the file has all five packet items from Path 1 before it goes out. Complete files get answered; incomplete files get stalled.

Day 7

If you were already denied, find the deadline on your denial letter and start the appeal -- or consciously choose the Zepbound or self-pay lane instead. A decision beats a stall.

Bonus

Set a calendar reminder for the first week of July. The Medicare Bridge launches July 1, and many plans make mid-year formulary updates around the same time -- worth a fresh look at your plan's drug list.

Check your GLP-1 coverage now — free, with a written report →

Shows coverage and prior-auth requirements for each medication before you spend a copay.

FAQ: Mounjaro, PCOS, and insurance

Is Mounjaro FDA-approved for PCOS?: No. Mounjaro is FDA-approved to improve blood sugar in people age 10 and up with type 2 diabetes. PCOS is not an approved use for Mounjaro or any GLP-1 medication, though a 72-week clinical trial is currently testing tirzepatide in women with PCOS.
Can my doctor prescribe Mounjaro for PCOS anyway?: Yes -- doctors can legally prescribe medicines off-label when they believe it's appropriate. But a prescription and a paid claim are two different things. Insurance covers the FDA-approved use, so an off-label PCOS prescription usually means paying cash.
Does insurance cover Mounjaro for PCOS if I have prediabetes or insulin resistance?: Usually not. Plans like Cigna state in writing that diabetes prevention is not a covered use for these drugs. Prediabetes and insulin-resistance labs are still valuable -- they can support Zepbound criteria at BMI 27-29.9, count toward the Medicare GLP-1 Bridge at BMI 27+, and strengthen an appeal -- they just don't unlock Mounjaro by themselves.
What diagnosis qualifies for Mounjaro coverage?: Type 2 diabetes. Lilly's prior-authorization guide points doctors to diabetes ICD-10 codes such as E11.65, E11.8, and E11.9, plus a recent A1c and medication history. Some plans also want metformin-related documentation; others focus on documented diabetes labs and records.
Does the Mounjaro savings card work if my insurance denies coverage?: Not for an off-label use. Lilly's terms require commercial insurance and a prescription for one of Mounjaro's FDA-approved uses -- type 2 diabetes. There's a $25 tier when your plan covers Mounjaro and a $499 tier when it doesn't, but the approved-use rule applies to both, and government insurance is excluded entirely.
Is Zepbound easier to get covered than Mounjaro for PCOS?: For most people without diabetes, yes -- it contains the same active ingredient (tirzepatide) with a weight-management approval: BMI 30+, or 27+ with a weight-related condition. The catch is your plan must include a weight-loss drug benefit, which 43% of plans did in Ro's 2024-2025 coverage-check report.
Does the new Medicare program cover Mounjaro?: No. The Medicare GLP-1 Bridge, starting July 1, 2026, covers Zepbound KwikPen, Wegovy, and Foundayo for weight reduction at a flat $50/month for eligible Part D enrollees. Mounjaro remains a regular Part D medication for covered uses like type 2 diabetes.
Does Medicaid cover Mounjaro for PCOS?: Generally no. State programs typically cover Mounjaro for type 2 diabetes with prior authorization, while excluding weight-loss use -- Medi-Cal Rx in California says this outright, and Massachusetts bars paying for obesity drugs by regulation. Rules vary by state, so check your state's formulary.
Does Mounjaro affect birth control?: It can. The label warns that birth-control pills may be less effective after starting tirzepatide or increasing the dose, and advises a non-pill or backup method for four weeks after starting and after each dose increase. With PCOS, weight loss can also improve ovulation -- so an unplanned-pregnancy risk can rise exactly when you'd least expect it.
Is compounded tirzepatide an option instead?: We don't recommend it as the path here. The FDA determined the tirzepatide shortage was resolved in December 2024, with wind-down deadlines for both 503A and 503B compounders. Compounded drugs are not FDA-approved, and once a shortage ends, making copies of available FDA-approved drugs faces legal restrictions. This guide sticks to FDA-approved routes with published prices.
What about Ozempic or Wegovy for PCOS?: Different medicine (semaglutide), different coverage logic. If your plan covers Wegovy but not Zepbound -- common on some Caremark plans -- start with our Mounjaro vs Wegovy for PCOS guide, then check coverage the same way.

How we built this page (and what we didn't do)

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. For this guide, our editorial team read the primary sources directly: FDA labeling via DailyMed for both Mounjaro and Zepbound, Lilly's Savings Card terms and prior-authorization guide, public payer policies from Cigna, Aetna, UnitedHealthcare, Blue Cross Blue Shield of Massachusetts, and Medi-Cal Rx, CMS's Medicare GLP-1 Bridge rules for beneficiaries and providers, KFF's Medicaid research, the 2023 international PCOS guideline, public appeal records from Massachusetts and New York, LillyDirect's self-pay terms, and Ro's published coverage-checker data.

What we did not do: verify your individual plan (impossible from here), promise any approval outcome (impossible for anyone), invent an author or a medical reviewer, or rank providers by what they pay us. Where a provider pays us a commission, we said so — and we listed the non-commission options (LillyDirect, TrumpRx, the Medicare Bridge) in the same tables anyway.

Prices and policies verified June 9, 2026. Scheduled for full re-verification in early July 2026, when the Medicare Bridge launches.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz and get a personalized action plan — the right path, the right questions, and the right next step for your exact situation.

Take the free 60-second matching quiz →Or check your coverage free with Ro →

Affiliate disclosure

Some links on this page pay us a commission. That never changes a price you pay, and it never changes a fact we report. Non-commission routes (LillyDirect, TrumpRx, Medicare Bridge) are listed in the same tables anyway — because hiding the cheapest legitimate option would make everything else on this page worthless.

Related guides from The RX Index

Related guides